Marc G H

Oct 14, 2024 | academic.oup.com | Eva M. M |Amsterdam UMC |Marc G H |Van Eijck

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-associated mortality, with a 5-year survival of 13%1. Localized (that is non-metastatic) PDAC is classified as resectable, borderline resectable (BR), or locally advanced (LA), based on the extent of vascular contact2. The combination of systemic chemotherapy and surgical resection results in the best long-term survival3. Neoadjuvant and induction treatment has become the standard of care for patients with BR and LA PDAC.